Trial · NCT02265796

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796, Phase 2, Completed, North Florida Foundation for Research and Education; results first posted 2017-12-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ranolazine Among Unrevascularized Chronic Stable Angina Patients. Trials, record NCT02265796. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02265796

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ranolazine Among Unrevascularized Chronic Stable Angina Patients
NCT number: NCT02265796
Status: Completed
Phases: Phase 2
Enrollment: 50 participants, actual
Lead sponsor: North Florida Foundation for Research and Education
Conditions: Angina
Interventions: Ranolazine, Sugar pill
First posted: 2014-10-16
Last updated: 2019-08-22
Results first posted: 2017-12-04

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Change in baseline to 16 weeks	The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life.Each of the 5 dimensions are scored by assigning eachresponse an ordinal value, beginning with 1 for the response that implies the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range1 / 3 Seattle Angina Questionnaire (SAQ)of the scale and multiplying by 100. No overall scale score is generated. Factors and Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life). .
Secondary	Subjective Well Being	Compare from baseline to month 4	overall feeling of well being determined from rating of excellent, good, fair or poor at baseline compared to same at month 4
Secondary	Ischemia Driven Revascularization or Hospitalization	4 month	Number of participants who reported adverse events for ischemia driven revascularization or hospitalization

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Change in baseline to 16 weeks	by intention to treat, 46 subjects had baseline and follow up SAQ data completed at 16 weeks	units on a scale	MEAN
SECONDARY	Subjective Well Being	Compare from baseline to month 4		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Ischemia Driven Revascularization or Hospitalization	4 month	the incidence of ischemia driven hospitalization or catheterization was assessed for all subjects.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group44

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Ranolazine	Physical Limitation baseline	48	Standard Deviation 25	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Sugar Pill	Physical Limitation baseline	50	Standard Deviation 20	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Ranolazine	Physical Limitation 16 weeks	40	Standard Deviation 19	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Sugar Pill	Physical Limitation 16 weeks	60	Standard Deviation 24	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Ranolazine	Physical Limitation group difference	-7	Standard Deviation 27	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Sugar Pill	Physical Limitation group difference	6	Standard Deviation 20	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Ranolazine	Angina Stability baseline	39	Standard Deviation 28	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Sugar Pill	Angina Stability baseline	37	Standard Deviation 28	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Ranolazine	Angina Stablility 16 weeks	58	Standard Deviation 26	units on a scale
Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks	Sugar Pill	Angina Stablility 16 weeks	55	Standard Deviation 27	units on a scale

1 to 10 of 44Source ClinicalTrials.gov

See all 44 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ranolazine	25
Overall Study	STARTED	Sugar Pill	25
Overall Study	COMPLETED	Ranolazine	22
Overall Study	COMPLETED	Sugar Pill	24
Overall Study	NOT COMPLETED	Ranolazine	3
Overall Study	NOT COMPLETED	Sugar Pill	1

Source ClinicalTrials.gov

Adverse events48

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	anxiety	Psychiatric disorders	Ranolazine	0	25	0
other	anxiety	Psychiatric disorders	Sugar Pill	1	25	1
other	dizziness	Nervous system disorders	Ranolazine	5	25	5
other	dizziness	Nervous system disorders	Sugar Pill	1	25	1
other	Bronchitis	Respiratory, thoracic and mediastinal disorders	Ranolazine	1	25	1
other	Bronchitis	Respiratory, thoracic and mediastinal disorders	Sugar Pill	0	25	0
other	Fainting	Nervous system disorders	Ranolazine	3	25	3
other	Fainting	Nervous system disorders	Sugar Pill	2	25	2
other	Musculoskeletal pain	Musculoskeletal and connective tissue disorders	Ranolazine	2	25	2
other	Musculoskeletal pain	Musculoskeletal and connective tissue disorders	Sugar Pill	3	25	3

1 to 10 of 48Source ClinicalTrials.gov

See all 48 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ranolazine	1	25
Total, all-cause mortality	Sugar Pill	0	25
Total, other adverse events	Ranolazine	17	25
Total, other adverse events	Sugar Pill	15	25
Total, serious adverse events	Ranolazine	5	25
Total, serious adverse events	Sugar Pill	4	25

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
28044265	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ranolazine vs Sugar Pill: Ischemia Driven Revascularization or Hospitalization	Trial comparisons
Ranolazine vs Sugar Pill: deaths from any cause	Trial comparisons
Ranolazine vs Sugar Pill: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02265796

GET https://conductscience.org/api/trials/v1/NCT02265796/results?page=2

API reference For AI assistants